Log in
Updated few hours ago

Magoola gets PhD, to lead FDA meeting on treatment of cancers

Mathias Magoola

Mathias Magoola

Matthias Magoola, the founder and chief executive officer of Dei Group of Companies, has been honored with a Professional Doctorate (PD) in Management from the European International University of France.

The university, headquartered in Paris, France, officially announced this prestigious award on February 19, 2024. Dr Magoola, an advanced therapeutics researcher and innovator, has spearheaded various medical research projects.

Notable among these projects is the development of new treatments for malaria using N-Isobutyll-3, 4-metheylenedioxy-trans-cinnamide compositions, which have been patented in the USA. His research endeavours have also resulted in the introduction of novel vaccines and treatments for HIV/HPV, malaria, cancer, and neurodegenerative disorders, including Alzheimer’s, Parkinson’s, and diabetes, also patented in the USA.

One of Dr Magoola’s groundbreaking inventions is the “mRNA-based vaccine composition for inducing immune response against HIV and HPV,” patented under certificate number 63921929 in the USA. With over 10 innovative patents focusing on advanced therapies, Dr Magoola is slated to lead a team of fellow scientists for a meeting at the Food and Drug Administration (FDA) of the USA next month to discuss their first product submission on a new innovation to treat cancers and severe anaemia, utilizing mRNA technology.

Dr Magoola has co-authored several publications that have undergone rigorous peer review and have been published by esteemed journals worldwide.

His latest study, “Synergistic Approaches in Neurodegenerative Therapeutics: Multi-Target Drug Innovative Interventions for Alzheimer’s Disease,” has been featured in Pharmaceuticals, a peer-reviewed, open-access journal of medicinal chemistry and related drug sciences. Additionally, his co-authored works include “Advances in Escherichia Coli-Based Therapeutic Protein Expression: Mammalian Conversion, Continuous Manufacturing, and Cell-Free Production,” and “mRNA and Synthesis-Based Therapeutic Proteins: A Non-Recombinant Affordable Option,” both published in the Biologics journal.

Dr Magoola regards his doctorate and publications as significant milestones in the battle against various incurable diseases, including neurodegenerative disorders, HIV/AIDS, HPV, and cancers.

“We have discovered innovative new ways to treat neurodegenerative disorders for the first time,” he remarked.

His publications and groundbreaking discoveries in treating various rare diseases have garnered global recognition, thereby enhancing the reputation of Ugandan researchers and authors worldwide.

In addition to his academic achievements, Magoola was honoured with the 10th International Excellence and Global Leadership award by Fame Times International Excellence Awards in Bangkok, Thailand, on February 24, 2024. He was commended for his visionary success and groundbreaking discoveries in advanced therapies.

Comments

0 #1 Nkuutu Kibedi 2024-02-29 11:36
Is this not the fellow who scammed us that he had " the coronavirus" drug, even though he knew that Conviq19 was a virus?

Is not this the fellow who is always in the news for his factory (that has not even began production)? Is this not the fellow who conned M7 about his medical prowess?
Report to administrator

Comments are now closed for this entry